← All Signals

🏥 FDA: CareFusion 213, LLC — Class II

healthcarebearishSource: FDA
80%Confidence
0Views
FDASource
2026-05-27Date

Summary

Sterility assurance failure in BD's PurPrep product could lead to infections, damaging brand trust and sales. This recall may pressure BD's medical device segment and invite regulatory fines.

Actionable: Assess BD's recall impact on revenue and reputation; consider hedging positions in medical device suppliers.

AI Confidence: 80%

Data Points

firmCareFusion 213, LLC
classificationClass II
statusOngoing
distributionNationwide in the USA
productBD PurPrep, Povidone-iodine 8.3% w/w (0.83% available iodine) with isopropyl alcohol 72.5% w/w Sterile Solution, 0.36 fl. oz. (10.5 mL) x 25 applicato

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now